DexCom, Inc. (DXCM) Analyst/Investor Day May 14, 2026 4:15 PM EDT
Company Participants
Jacob Leach – President, CEO & Director
Jon Coleman – Executive VP & Chief Commercial Officer
Jereme Sylvain – Executive VP, CFO & Chief Accounting Officer
Sean Christensen – Vice President of Finance and Investor Relations
Conference Call Participants
David Roman – Goldman Sachs Group, Inc., Research Division
Jeffrey Johnson – Robert W. Baird & Co. Incorporated, Research Division
Larry Biegelsen – Wells Fargo Securities, LLC, Research Division
Joanne Wuensch – Citigroup Inc., Research Division
Christopher Pasquale – Nephron Research LLC
Matthew O’Brien – Piper Sandler & Co., Research Division
Richard Newitter – Truist Securities, Inc., Research Division
Joshua Jennings – TD Cowen, Research Division
Shagun Singh Chadha – RBC Capital Markets, Research Division
Presentation
Operator
Welcome to the 2026 Dexcom Investor Day. As a reminder, this presentation contains forward-looking statements. Please note our safe harbor statement included here as well as our filings with the Securities and Exchange Commission.
[Presentation]
Operator
Please welcome President and Chief Executive Officer, Jake Leach.
Jacob Leach
President, CEO & Director
Hello, everybody, and welcome to Dexcom’s 2026 Investor Day. It’s great to see all of you here. Thank you so much for joining us. I’m Jake Leach, President and CEO. And today, we will review our priorities that are designed to drive the next phase of growth for Dexcom. There’s many things that make Dexcom extraordinary, but one that really stands out to me is our ability to imagine and build a prosperous future while simultaneously impacting the lives of millions of people every day, helping improve their diabetes management. And at the same time, we’re lowering the overall cost of care for this population. There are 3 key drivers that are going to define the next phase of Dexcom’s journey. First, we have an advanced product portfolio that is focused on meeting valuable, distinct, highly important things for our customers. Second, the clinical and economic value we
